Wall Street Zen Upgrades Denali Therapeutics (NASDAQ:DNLI) to Hold

Denali Therapeutics (NASDAQ:DNLI) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other research analysts have also weighed in on DNLI. Morgan Stanley raised their price objective on Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Wedbush reaffirmed an “outperform” rating and issued a $26.00 target price on shares of Denali Therapeutics in a report on Monday, July 13th. Deutsche Bank Aktiengesellschaft boosted their target price on Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. JPMorgan Chase & Co. started coverage on Denali Therapeutics in a research note on Monday, July 13th. They set an “overweight” rating and a $29.00 price target for the company. Finally, B. Riley Financial increased their price target on Denali Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, August 25th. Thirteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Denali Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $35.85.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $18.41 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37. The firm has a fifty day moving average price of $21.16 and a 200 day moving average price of $21.73. Denali Therapeutics has a fifty-two week low of $13.75 and a fifty-two week high of $27.30. The firm has a market cap of $2.94 billion, a price-to-earnings ratio of -6.48 and a beta of 1.02.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The company had revenue of $3.60 million for the quarter, compared to the consensus estimate of $2.15 million. During the same period last year, the firm earned ($0.72) earnings per share. As a group, sell-side analysts expect that Denali Therapeutics will post -2.70 earnings per share for the current fiscal year.

Insider Buying and Selling at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 2,768 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $23.44, for a total value of $64,881.92. Following the completion of the transaction, the insider owned 278,995 shares of the company’s stock, valued at approximately $6,539,642.80. This trade represents a 0.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Denali Therapeutics during the second quarter worth approximately $26,000. Global Retirement Partners LLC purchased a new stake in Denali Therapeutics during the second quarter valued at approximately $28,000. Nykredit A S bought a new stake in shares of Denali Therapeutics in the 2nd quarter valued at approximately $38,000. Manchester Capital Management LLC lifted its stake in shares of Denali Therapeutics by 5,505.6% in the 3rd quarter. Manchester Capital Management LLC now owns 2,018 shares of the company’s stock valued at $42,000 after purchasing an additional 1,982 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Denali Therapeutics by 44.4% in the 3rd quarter. GAMMA Investing LLC now owns 2,236 shares of the company’s stock valued at $46,000 after purchasing an additional 687 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.